Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Torii Enjoys Stellar Performance from Corectim, 1st JAK Med for Atopic Dermatitis
September 30, 2020
- Alnylam Seeks Japan Approval of RNAi Drug Givosiran for Acute Hepatic Porphyrias
September 30, 2020
- JCR Files Sakigake-Designated Pabinafusp Alfa for Hunter Syndrome
September 30, 2020
- 2nd GPCR-Targeted Candidate Enters Clinic under Sosei/Pfizer’s Drug Discovery Alliance
September 29, 2020
- Otsuka Files Japan NDA for Atopic Dermatitis Drug Difamilast
September 29, 2020
- AbbVie Files New Dosage Forms for Skyrizi in Japan
September 29, 2020
- Approval Now in Hand, CureApp Looks at Collaborations with Drug Makers to Push Therapeutic Apps
September 29, 2020
- Sawai, Susmed Pair Up in Digital Healthcare Field
September 28, 2020
- Shionogi Delays Saliva-Based COVID-19 Test Launch to December
September 25, 2020
- Astellas, Univ. of Pittsburgh Ink Research Pact for Dry AMD
September 25, 2020
- Taiho Hooks Up with MD Anderson on Refractory Cancers
September 25, 2020
- Sawai Can Set Itself Apart from Competitors in Post-80% Generic Era through Development Strategy: President
September 25, 2020
- Daiichi Sankyo Sets Up Subsidiary in Vietnam
September 25, 2020
- Ohara Files Neuroblastoma Drug Dinutuximab in Japan
September 25, 2020
- LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
September 24, 2020
- Opdivo Improves PFS in 1st Line Gastric Cancer: Asian PII/III Trial
September 24, 2020
- Padcev Extends Survival in Bladder Cancer, Trial Stopped Early: Astellas/Seattle Genetics
September 24, 2020
- Sun Pharma Launches Ilumya; Its First Innovative Med in Japan
September 24, 2020
- Sumitomo Dainippon Sets Up Subsidiary in Taiwan
September 24, 2020
- Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…